Larson Financial Group
MLYS icon

Larson Financial Group’s Mineralys Therapeutics MLYS Stock Holding History

Larson Financial Group’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$151 Hold
6
– – ﹤0.01% 3719
2026
Q2 		$162 Hold
6
– – ﹤0.01% 3618
2026
Q1 		$163 Sell
6
-148
-96% -$4.34K ﹤0.01% 3476
2025
Q4 		$5.59K Buy
154
+124
+413% +$4.97K ﹤0.01% 2409
2025
Q3 		$1.14K Buy
30
+24
+400% +$519 ﹤0.01% 2882
2025
Q2 		$81 Buy
+6
New +$87 ﹤0.01% 3190

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Larson Financial Group's MLYS Position: Q3 2026 in Review

Larson Financial Group held its Mineralys Therapeutics (MLYS) position steady in Q3 2026 at 6 shares worth $151. The position accounts for ﹤0.01% of the portfolio, ranked #3719.

Larson Financial Group first reported a position in MLYS in Q2 2025 and has held it in 6 quarters since. The position peaked at $5.59K in Q4 2025. 88 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Larson Financial Group held 6 shares of Mineralys Therapeutics worth $151 as of Q3 2026.
  • Larson Financial Group left its Mineralys Therapeutics share count unchanged in Q3 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #3719 holding.
  • Larson Financial Group first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Larson Financial Group's Mineralys Therapeutics position peaked at $5.59K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.